Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Neurochem's new agent will become the clinical gold standard for the treatment of Alzheimer's disease in 2008. According to the new report entitled Alzheimer's Disease: Turning Physician Insight into Projected Patient Share, the drug, currently known as tramiprosate (also called NC-758), will provide greater efficacy than Eisai/Pfizer's Aricept, the current gold standard.

"As a disease-modifying drug, tramiprosate promises to delay cognitive, functional, and overall clinical decline longer than Aricept, a much-needed improvement over currently available treatments, which address only the symptoms of Alzheimer's disease," said Andrea Witt, Ph.D., director at Decision Resources.

About Alzheimer's Disease: Turning Physician Insight into Projected Patient Share

Alzheimer's Disease: Turning Physician Insight into Projected Patient Share covers the current and future state of the Alzheimer's disease drug market. The report includes:

  -- More than 3,000 physician responses that define drug attributes that      drive prescription now and in the future.      -- Clinical end point tradeoffs that are most influential to         physicians.      -- Areas of unmet need with highest potential.      -- Benchmark trial results for specific drug opportunities.      -- Patient share potential for emerging therapies and target product         profiles.   -- Decision Resources proprietary analysis of commercial factors that      accelerate or constrain a drug's market potential.      -- Promotion: DTC spend, detailing intensity.      -- Reimbursement: formulary tier, prior approval restriction, quantity         limits.      -- Labeling: black box warnings, approved patient segments,         contraindications.      -- Competition: order of entry, pricing, generic entry, pipeline sales         forecast.      -- Medical practice: decision trees, treating physician type, line of         therapy.   -- Comparisons of the key clinical attributes of current and emerging      therapies in the areas of efficacy, safety, and delivery.   -- Analysis and supporting data that identifies the clinical "Gold      Standard" now and over the next ten years.   -- Key insights as to which clinical end points have the greatest      influence on physician decision-making.  

The report can be purchased by contacting Decision Resources. Members of the media may request a complimentary copy or an interview with an analyst.

About Decision Resources

Decision Resources, Inc., ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall   Decision Resources, Inc.   781-296-2563 

SOURCE: Decision Resources

CONTACT: Elizabeth Marshall of Decision Resources, +1-781-296-2563, or

Amgen's Upcoming RANKL Inhibitor Denosumab Will Become the Clinical Gold Standard for the Treatment of Osteoporosis by 2010

View Now